<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349271</url>
  </required_header>
  <id_info>
    <org_study_id>EMRTCC-CHG</org_study_id>
    <nct_id>NCT00349271</nct_id>
  </id_info>
  <brief_title>Cell Therapy in Chagas Cardiomyopathy</brief_title>
  <official_title>Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Financiadora de Estudos e Projetos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Brazil</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine effect of cell therapy in patients with severe
      dilated cardiomyopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a double-blind placebo controlled randomized clinical trial to
      evaluate the efficacy of bone marrow derived stem cell implants in 300 bazillion patients
      with dilated cardiomyopathy and heart failure in class III or IV of the New York Heart
      Association.

      The primary endpoint of this study is to evaluate the effect of the autologous bone marrow
      stem cell implant in the increase of the ejection fraction of the left ventricle in
      comparison with a control group, under optimized therapy for dilated cardiomyopathy.
      Secondary endpoints will evaluate the alteration in NYHA functional class, mortality rate,
      physical capacity (by ergoespirometry), life quality (Minnesota questionnaire) and pulmonary
      congestion in dilated cardiomyopathy patients the received the autologous bone-marrow stem
      cell implant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change the sample size due to smaller variance than expected
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>increase of the ejection fraction of the left ventricle</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death by any cause within 1 year of intervention</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in life quality as estimated by Minnesota living with Heart Failure Questionnaire at six months and baseline</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in NYHA functional class at six months and baseline</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent number of patients that reached an absolute increase of 5% in ejection fraction at six and twelve months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Chagas Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Stem Cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem Cell therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standart therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standart therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell</intervention_name>
    <description>Stem cell</description>
    <arm_group_label>Stem Cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastime (G-CSF)</intervention_name>
    <description>Filgrastime (G-CSF)</description>
    <arm_group_label>Stem Cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standart therapy</intervention_name>
    <description>All drug with clinical evidence of benefical effect in Chagas disease</description>
    <arm_group_label>Standart therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of dilated cardiomyopathy according to WHO criteria

          -  Syndromic heart failure in functional class III or IV of the NYHA

          -  Enrollment and continuous follow-up in cardiac out-patient clinic

          -  Adequate medical therapy after optimization therapy

          -  Echocardiogram with an ejection fraction equal to or less than 35% by Simpson's rule

        Exclusion Criteria:

          -  Valvular diseases, except functional mitral or tricuspid reflow

          -  Coronariography showing a significant lesion (obstruction of at least 50% of the lumen
             in the troncus or the main arteries - LAD, CX, RC) in one or more arteries

          -  Serologic diagnosis for Chagas disease or at least two of the following criteria:
             epidemiology, right bundle branch block, anterior hemi-block, apical aneurism

          -  Sustained ventricular tachycardia

          -  Abusive use of alcohol or illicit drugs

          -  Pregnancy

          -  Use of cardio toxic drugs

          -  Any co-morbidity with impact in life expectancy in 2 years

          -  Renal function compromised (creatinine above 2 mg/dl)

          -  Definitive implant of pace-makers, resynchronizers and CDIs

          -  Heart failure with symptoms initiating less than 1 year ago

          -  Active systemic arterial hypertension or history of hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo R Santos, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de pesquisa Gonzalo Muniz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilson Feitosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Isabel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INCL - National Institute of Cardiology Laranjeiras</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22.240-006</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Brazil</investigator_affiliation>
    <investigator_full_name>Bernardo Rangel Tura</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chagas Cardiomyopathy</keyword>
  <keyword>Dilated Cardiomyopathy</keyword>
  <keyword>stem cells</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Chagas Cardiomyopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

